The Development and Clinical Application of Hybridomas
Having succeeded in demonstrating its value in basic research, hybridoma technology has now begun to make significant contributions to clinical medicine. The ability of this technology to permit the development of large quantities of homogeneous highly specific antibodies to virtually all antigenic determinants is being particularly explored in the field of oncology. Although it is too early to know if monoclonal antibodies specific for human tumors can be used in vivo to treat these tumors, sufficient data is now available to indicate that diagnosis, prognosis and ex vivo therapy of human tumors can be accomplished even with monoclonal antibodies which are not completely specific for the tumor. Attempts are now being made to develop monoclonal antibodies to allergens for use in identification of components responsible for an allergic effect and to define the biologically active structures of the allergen. The future availability of human hybridoma antibodies reactive to allergens of clinical significance could permit a clearer understanding of the properties of the allergen responsible for its activity and may lead to appropriate immunotherapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
Document Type: Research Article
Publication date: 1982-03-01
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites